PHMR

Decision 
Recommended with restrictions
Indication
In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

Decision Detail

Following an abbreviated submission, olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) is accepted for restricted use within NHSScotland. SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Summary

SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis. Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment choice that combines antihistamine and glucocorticoid in a single nasal spray.

About PHMR

Our experience